LEXICON PHARMACEUTICALS, INC.
LXRXNasdaqHealthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $49.8M | $6.0M | $1.1M | $0 | $0 | $23.4M |
| Operating income | −$48.9M | −$197.1M | −$171.8M | −$100.8M | −$87.1M | −$47.8M |
| Net income | −$50.3M | −$200.4M | −$177.1M | −$101.9M | −$87.8M | −$58.6M |
| Total assets | $185.0M | $298.4M | $229.4M | $194.3M | $136.9M | $203.8M |
| Total liabilities | $77.4M | $152.5M | $136.3M | $77.2M | $23.3M | $47.4M |
| Equity | $107.5M | $145.9M | $93.1M | $117.1M | $113.6M | $156.4M |
| EPS (diluted) | $-0.14 | $-0.63 | $-0.80 | $-0.62 | $-0.60 | $-0.53 |
| Shares out. | 361.5M | 246.2M | 188.7M | 165.7M | 145.7M | 144.4M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- −98.2%
- Net margin
- −101.1%
- Return on equity
- −46.8%
- Return on assets
- −27.2%
- Return on capital (ROCE)
- −29.8%
- Liabilities / assets
- 41.9%
- Debt / equity
- 0.72×
- Book value / share
- $0.30
- Revenue growth (YoY)
- 729.9%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -33.00distress
- Accruals / assets
- 9.5%moderate
- Beneish M-Score
- 4.43elevated
- Piotroski F-Score
- 4/9mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 severe● 4 warning● 2 good- Altman Z″ in the distress zone
- Operating losses (negative operating margin)
- Reported a net loss
- Negative operating cash flow
- Beneish M-Score elevated — earnings-manipulation screen flag
- Revenue is growing year-over-year
- Conservative leverage (liabilities < 50% of assets)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Clinical trials
ClinicalTrials.gov · ongoing · next readout firstInterventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Invus Global Management, LlcActivist (13D)May 8, 2026
- Fmr LlcPassive (13G)Jul 8, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 26.1M | 6.2 | +9.6% |
| Apr 30, 2026 | 23.9M | 13.6 | +0.8% |
| Apr 15, 2026 | 23.7M | 11.6 | +3.2% |
| Mar 31, 2026 | 22.9M | 9.1 | +1.1% |
| Mar 13, 2026 | 22.7M | 7.1 | -1.9% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Results of operationsMay 7, 2026
- Entered a material agreement · New financial obligation · Unregistered equity sale · Regulation FD disclosureMay 6, 2026
- Entered a material agreement · Unregistered equity sale · Amended charter or bylaws · Shareholder voteApr 30, 2026
- Results of operationsMar 5, 2026
- Entered a material agreement · Unregistered equity sale · Modified shareholder rights · Amended charter or bylaws · Regulation FD disclosureFeb 2, 2026
- Results of operations · Regulation FD disclosure · Other material eventJan 29, 2026
- Other material eventNov 10, 2025
- Other material eventNov 6, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- 4May 8, 2026
- SCHEDULE 13D/AMay 8, 2026
- 10-QMay 7, 2026
- 8-KMay 7, 2026
- 8-KMay 6, 2026
- 4PRIMARY DOCUMENTMay 4, 2026
- 4PRIMARY DOCUMENTMay 4, 2026
- 4PRIMARY DOCUMENTMay 4, 2026
- 4PRIMARY DOCUMENTMay 4, 2026
- 4PRIMARY DOCUMENTMay 4, 2026
- 4PRIMARY DOCUMENTMay 4, 2026
- 4PRIMARY DOCUMENTMay 4, 2026
- 8-KApr 30, 2026
- ARSANNLRPTMar 16, 2026
- DEFA14ADEF 14AMar 16, 2026
Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.